ReviewHepatology (Baltimore, Md.)2010
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.
Review in Hepatology (Baltimore, Md.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03354247 (Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Liver Disease), which is not on this map. Cited by 992 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Liver Disease
Who cites it
992 citing papers in PubMed, 4 syntheses or guidelines pooled it, 2,066 citations in OpenAlex.
- Association between metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease and chronic kidney disease: a systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2026Pooled it
- Anti-Obesity Effects of Sulphated Polysaccharides Derived from Marine Macro Algae or Seaweeds: A Systematic Review and Meta-Analysis.Marine drugs · 2024Pooled it
- Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis.Cardiovascular diabetology · 2024Pooled it
- The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review.Journal of translational medicine · 2024Pooled it
- A polyphenol fraction from Rosa multiflora var. platyphylala reduces body fat in overweight humans through appetite suppression - a randomized, double-blind, placebo-controlled trial.BMC complementary medicine and therapies · 2024Trial
- Neuroendocrine regulation of adipose partitioning in polyendocrine metabolic ovarian syndrome: the gut-brain-adipose axis.Journal of endocrinological investigation · 2026Review
- Relationship Between Hypovitaminosis C, Obesity, and Features of Metabolic Syndrome-A Narrative Review.Nutrition reviews · 2026Review
- Predictors of Liver Steatosis Progression Among People Living With HIV in Low- and Middle-Income Countries: A Multicentre Longitudinal Study.Journal of the International AIDS Society · 2026Article
- Article
- Steatotic Liver Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Case Series and Literature Review.Hematology reports · 2026Article
- Chronic infection and metabolic stress: a converging axis driving hypertension and metabolic dysfunction-associated steatotic liver disease outcomes.American journal of hypertension · 2026Review
- Hepatic LGALS4 Alleviates Diet-Induced Steatosis by Promoting AMPK-Dependent Fatty Acid Oxidation.Diabetes, obesity & metabolism · 2026Article
- National and state-level trends in digestive diseases in the United States, 1990 to 2021.Proceedings (Baylor University. Medical Center) · 2026Article
- Targeting Nuclear Import of Thyroid Hormone Receptor Alpha with Natural Polyphenols: Potential Mechanism for Lipolysis in Metabolic Dysfunction-Associated Steatotic Liver Disease.Current issues in molecular biology · 2026Article
- A pan-tissue multi-omics resource atlas of coordinated immune, metabolic, and fibrotic alterations in diet-induced MASH.iScience · 2026Article
- The anti-obesity and hepatoprotective effects of bacterial cyclodipeptides in a rat obesity model involve aquaporins, inflammatory factors, and GAB1 modulation.Journal of physiology and biochemistry · 2026Article
- Myeloid MMP14 couples extracellular proteolysis to inflammatory and metabolic remodeling during obesity.Cell reports · 2026Article
- Apabetalone Drives a Metabolic Shift Towards Ketogenesis and Reduces Liver Steatosis in Diet-Induced Obesity Mice.Biomedicines · 2026Article
- Association Between Metabolic Obesity Phenotypes and Alcohol-Associated Fatty Liver Disease Among US Adults: A NHANES 2013-2018 Analysis.Journal of clinical medicine · 2026Article
- UCP1-Dependent Thermogenic Adipose Tissue in Human Disease: Adipose-Centered Mechanisms, Biomarker Limitations, and Translational Perspectives.International journal of molecular sciences · 2026Review
932 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Obesity is associated with an increased risk of nonalcoholic fatty liver disease (NAFLD). Steatosis, the hallmark feature of NAFLD, occurs when the rate of hepatic fatty acid uptake from plasma and de novo fatty acid synthesis is greater than the rate of fatty acid oxidation and export (as triglyceride within very low-density lipoprotein). Therefore, an excessive amount of intrahepatic triglyceride (IHTG) represents an imbalance between complex interactions of metabolic events. The presence of steatosis is associated with a constellation of adverse alterations in glucose, fatty acid, and lipoprotein metabolism. It is likely that abnormalities in fatty acid metabolism, in conjunction with adipose tissue, hepatic, and systemic inflammation, are key factors involved in the development of insulin resistance, dyslipidemia, and other cardiometabolic risk factors associated with NAFLD. However, it is not clear whether NAFLD causes metabolic dysfunction or whether metabolic dysfunction is responsible for IHTG accumulation, or possibly both. Understanding the precise factors involved in the pathogenesis and pathophysiology of NAFLD will provide important insights into the mechanisms responsible for the cardiometabolic complications of obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.